Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

988726

	registered interest
	date	16/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Data Protection
	house id	1
	legislature	25259 pref label House of Commons
	question text	‘To ask the Secretary of State for Health and Social Care, how many subject access requests have been made to GP surgeries since the introduction of the General Data Protection Regulation.
	tabling member constituency	Warrington South
	tabling member printed	Faisal Rashid
	uin	180307
	answer	answer is ministerial correction date of answer 24/10/2018 answer text <p>This information is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/10/2018 12:35:34 answering member 4067 label Biography information for Steve Brine
	tabling member	4670 label Biography information for Faisal Rashid

867296

	registered interest
	date	20/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	What the timetable is for the implementation of the faecal immunochemical test for bowel cancer screening.
	tabling member constituency	Eastbourne
	tabling member printed	Stephen Lloyd
	uin	904478
	answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>The UK National Screening Committee has recommended that the faecal immunochemical test (FIT) be the primary screening test for bowel cancer and NHS England remains absolutely committed to implementing FIT in 2018/19.</p><p> </p><p>NHS England is working with Public Health England to finalise a number of practical arrangements around sensitivity, production and distribution of FIT kits, and diagnostic and pathology workforce capacity to ensure that when FIT is implemented, it is sustainable.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 17:31:43 answering member 4067 label Biography information for Steve Brine
	tabling member	3968 label Biography information for Stephen Lloyd

809129

	registered interest
	date	19/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	What recent assessment he has made of trends in the level of fines in relation to dental and prescription charges.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	903036
	answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>The NHS Business Services Authority (NHS BSA) issues penalty charge notices (PCNs) for incorrect claims for exemption from National Health Service dental and prescription charges.</p><p>To ensure the integrity of the exemption system the NHS BSA has recently increased the number of checks. In 2016/17, 365,181 PCNs for dental charges and 975,065 for prescription charges were issued. This represents an increase of 90.11% and 90.23%, respectively, on 2015/16. There is a clear process for patients to appeal a PCN if they believe it is unjustified.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/12/2017 17:09:22 answering member 4067 label Biography information for Steve Brine
	tabling member	4471 label Biography information for Rachael Maskell

993447

	registered interest
	date	23/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Flour: Folic Acid
	house id	1
	legislature	25259 pref label House of Commons
	question text	What progress he has made on implementing proposals for the mandatory fortification of flour with folic acid.
	tabling member constituency	Cumbernauld, Kilsyth and Kirkintilloch East
	tabling member printed	Stuart C. McDonald
	uin	907229
	answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>The Government is continuing to review advice from our expert advisory groups on safe levels of folate intake. Alongside this, we will be issuing a public consultation on the issue of adding folic acid to flour. This will explore this complex issue in detail and allow us to take an informed decision on whether to introduce mandatory fortification of flour. We will announce the date for the consultation soon.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:43:47 answering member 4067 label Biography information for Steve Brine
	tabling member	4393 label Biography information for Stuart C McDonald

837681

	registered interest
	date	06/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Labour Turnover
	house id	1
	legislature	25259 pref label House of Commons
	question text	What estimate his Department has made of the number of GPs who plan to leave general practice in the next five years; and if he will make a statement.
	tabling member constituency	Rochdale
	tabling member printed	Tony Lloyd
	uin	903795
	answer	answer is ministerial correction date of answer 06/02/2018 answer text <p>We know that one of the main reasons GPs leave general practice is retirement. That is why we have put in place comprehensive measures to ensure we meet our commitment of an extra 5,000 GPs in the NHS by 2020. GP Career Plus, the GP Retention Scheme and the National GP Induction and Refresher Scheme will all help get valuable experienced GPs back into our NHS. 3,157 GP training places were also filled in 2017 – the highest number ever.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/02/2018 15:44:28 answering member 4067 label Biography information for Steve Brine
	tabling member	450 label Biography information for Tony Lloyd

809126

	registered interest
	date	19/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	What estimate he has made of the number of patients with Erythropoietic Protoporphyria.
	tabling member constituency	Newport East
	tabling member printed	Jessica Morden
	uin	903031
	answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>In 2016/17 there were 54 National Health Service admissions in England with a primary diagnosis of Erythropoietic Protoporphyria.</p><p> </p><p>Whilst the numbers of people with a particular rare disease can be very small, 3.5 million people in the United Kingdom have a rare disease. We know, as with the hon. Member’s constituent, that these diseases can have a heart-breaking impact on a person’s health.</p><p> </p><p>That‘s why the UK is committed to building on our position as a world-leader in the diagnosis and treatment of rare diseases.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/12/2017 17:07:30 answering member 4067 label Biography information for Steve Brine
	tabling member	1548 label Biography information for Jessica Morden

993448

	registered interest
	date	23/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Foetal Alcohol Spectrum Disorder
	house id	1
	legislature	25259 pref label House of Commons
	question text	What assessment he has made of the proportion of children born in the UK with foetal alcohol spectrum disorders in each of the last five years.
	tabling member constituency	Sefton Central
	tabling member printed	Bill Esterson
	uin	907231
	answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>Foetal alcohol syndrome disorders can have a significant impact on the early years development of children, their behaviours and their life chances.</p><p>Public Health England collects some data on fetal alcohol sydrome, but we recognise that this data does not reflect the range of fetal alcohol spectrum disorders (FASD), as these are very difficult to diagnose. That is why we are engaging experts and those affected by FASD to explore what more could be done to improve our understanding.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:44:55 answering member 4067 label Biography information for Steve Brine
	tabling member	4061 label Biography information for Bill Esterson

793035

	registered interest
	date	21/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Tobacco
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State, when his Department plans to complete the approvals process to enable the competition for a grant to support implementation of the Tobacco Control Plan to proceed.
	tabling member constituency	Harrow East
	tabling member printed	Bob Blackman
	uin	114820
	answer	answer is ministerial correction date of answer 29/11/2017 answer text <p>The Department is still considering the scope and procurement process for grants to support the implementation of the Tobacco Control Plan. Cabinet Office standards require all new grants to be subject to competition. Our intention is to make any future grant available on a multi-year basis, subject to an appropriate business case and satisfactory performance on the part of the funded bodies.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 114819 114822 114824 question first answered 29/11/2017 14:39:07 answering member 4067 label Biography information for Steve Brine
	tabling member	4005 label Biography information for Bob Blackman

793037

	registered interest
	date	21/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Tobacco
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State, what plans his Department has to open the competition for the grant to support implementation of the Tobacco Control Plan for England this year.
	tabling member constituency	Harrow East
	tabling member printed	Bob Blackman
	uin	114822
	answer	answer is ministerial correction date of answer 29/11/2017 answer text <p>The Department is still considering the scope and procurement process for grants to support the implementation of the Tobacco Control Plan. Cabinet Office standards require all new grants to be subject to competition. Our intention is to make any future grant available on a multi-year basis, subject to an appropriate business case and satisfactory performance on the part of the funded bodies.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 114819 114820 114824 question first answered 29/11/2017 14:39:07 answering member 4067 label Biography information for Steve Brine
	tabling member	4005 label Biography information for Bob Blackman

828794

	registered interest
	date	23/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Kidney Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State, if he will take steps to ensure that people with diabetes are offered urine and blood tests to check for chronic kidney disease.
	tabling member constituency	Sunderland Central
	tabling member printed	Julie Elliott
	uin	124426
	answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) has published guidance on ‘Chronic kidney disease in adults’ which sets out best practice for clinicians on the diagnosis, treatment, care, and support of patients with chronic kidney disease (CKD). The guidance also includes recommendations for those at risk of developing CKD, including people with diabetes. NHS England expects commissioners to take account of NICE guidelines when delivering services.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 31/01/2018 12:34:13 answering member 4067 label Biography information for Steve Brine
	tabling member	4127 label Biography information for Julie Elliott

793032

	registered interest
	date	21/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Anaemia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State of Health, what steps the Department is taking to promote awareness and improve the rate of diagnosis of anaemia.
	tabling member constituency	North East Derbyshire
	tabling member printed	Lee Rowley
	uin	114817
	answer	answer is ministerial correction date of answer 29/11/2017 answer text <p>Iron deficiency anaemia is the most prevalent type of anaemia and is also the most common deficiency in the world, affecting over 2 billion people worldwide. NHS Choices provides advice on the symptoms of iron deficiency anaemia, such as fatigue, palpitations, pale complexion and advises anyone experiencing those symptoms speak to their general practitioner (GP). NHS Choices also provides advice on the less common types of anaemia related to levels of vitamin B12 or folate.</p><p> </p><p>It is the responsibility of GPs, using their clinical judgement and supported by relevant guidance, to arrange the appropriate tests and investigations that may lead to a diagnosis. The full blood count, one the most commonly used tests in the National Health Service, is a broad screening tool used to provide a picture of patient health and check for indications of disorders such as anaemia, infection, and many other diseases.</p><p> </p><p>A range of guidance on the further testing and treatment of all types anaemia is available from sources including the National Institute for Health and Care Excellence Clinical Knowledge Summaries (CKS) website. The CKS information on iron deficiency anaemia can be found at the following link:</p><p> </p><p><a href="https://cks.nice.org.uk/anaemia-iron-deficiency" target="_blank">https://cks.nice.org.uk/anaemia-iron-deficiency</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/11/2017 14:42:34 answering member 4067 label Biography information for Steve Brine
	tabling member	4652 label Biography information for Lee Rowley

751345

	registered interest
	date	12/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dental Services: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the recently concluded pilot on improving access to primary care dentistry in the Bradford City, Bradford Districts and North Kirklees Clinical Commissioning Group areas, what plans he has to publish his assessment of that pilot; and whether he has plans to provide ongoing funding to improve access to primary care dentistry.
	tabling member constituency	Bradford South
	tabling member printed	Judith Cummins
	uin	4705
	answer	answer is ministerial correction date of answer 17/07/2017 answer text <p>The primary care dental access pilot, which began on 9 January 2017, was established to build additional capacity in dental practices and provide more appointments for the patients of Kirklees, Dewsbury and Bradford.</p><p> </p><p>The scheme, which was originally due to end on 31 March 2017, proved to be successful, so was extended until 30 June 2017. The results of this are currently being analysed and NHS England will make the findings available shortly.</p><p> </p><p>NHS England has also confirmed that a costed commissioning plan, based on these findings and the needs of the population, will be considered by the NHS England Yorkshire and Humber Director team over the summer of 2017 and an approach agreed to improve capacity in identified areas.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/07/2017 12:56:35 answering member 4067 label Biography information for Steve Brine
	tabling member	4391 label Biography information for Judith Cummins

759361

	registered interest
	date	11/09/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Tobacco
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the publication of Towards a smoke-free generation: a tobacco control plan for England in July 2017 by his Department, if he will (a) create a strategy to reduce the consumption of and (b) publish a report on the consumption of chewing tobacco primarily by South Asian women.
	tabling member constituency	Preston
	tabling member printed	Mr Mark Hendrick
	uin	9830
	answer	answer is ministerial correction date of answer 14/09/2017 answer text <p>Towards a smoke free generation: a tobacco control plan for England, sets out national ambitions to further reduce use of all tobacco products across the population in England. We have no plans to produce either a separate strategy to address, or a report on, the consumption of chewing tobacco by South Asian women.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/09/2017 13:50:10 answering member 4067 label Biography information for Steve Brine
	tabling member	473 label Biography information for Sir Mark Hendrick

781421

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Illnesses: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on the medicine-taking behaviour of patients who rely on regular and multiple medications to prevent symptoms of long-term conditions.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110622
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110619 110620 110621 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781420

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Illnesses: Pre-payment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on patients with a long-term condition who have already purchased a prescription prepayment certificate.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110621
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110619 110620 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781417

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Illnesses: Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on patients with (a) inflammatory bowel disease and (b) a long-term condition.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110618
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110619 110620 110621 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781419

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments: Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on access to medications for (a) children, (b) older people and (c) other vulnerable people.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110620
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110619 110621 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

781418

	registered interest
	date	31/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on (a) the management of urgent care services and (b) the number of hospital admissions.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	110619
	answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110620 110621 110622 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

746704

	registered interest
	date	29/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sugar
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the oral contribution by the former Under-Secretary of State for Health on 21 March 2017, Official Report, Column 775, what assessment he has made of the effect of the Food and Drink Federation's decision not to introduce the Government's 20 per cent optional reduction in sugar content in its members' products by 2020 on his Department's policies to tackle (a) childhood obesity and (b) childhood tooth decay.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	2048
	answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>There has been no assessment made of the effect of Food and Drink Federation members’ compliance or non-compliance in achieving the 20% reduction in sugar content of key products contributing to children’s intakes by 2020 on childhood obesity or childhood tooth decay.</p><p> </p><p>In ‘Sugar reduction: The evidence for action’, published in October 2015, Public Health England (PHE) undertook modelling work to estimate the potential health impact and wider economic benefits of achieving the average population intake recommendation for sugar. This modelling found that achieving this over a 10-year period would result in 4,100 premature deaths and 204,000 cases of dental caries being averted, resulting in a total cost saving to the National Health Service of £484 million.</p><p> </p><p>PHE encourages all businesses to achieve the reductions in sugar as set out in ‘Childhood obesity: a plan for action’. A detailed assessment of industry’s progress will be published in March 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2017 11:13:15 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

755820

	registered interest
	date	04/09/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drugs: North East
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the latest statistical bulletin published by the Office for National Statistics on deaths related to drug poisoning, what steps he is taking to address the disproportionately high drug mortality rate in the North East.
	tabling member constituency	Easington
	tabling member printed	Grahame Morris
	uin	7218
	answer	answer is ministerial correction date of answer 12/09/2017 answer text <p>Local authorities are responsible for commissioning effective drug and alcohol prevention and treatment services based on an assessment of local need. Public Health England (PHE) supports local authorities to do this, by providing bespoke data, value for money tools, topical briefings, and advice on good practice to help local authorities meet the needs of their local population. In the North East, PHE work to help local areas prevent drug-related deaths includes:</p><p> </p><p>- running forums and networks to facilitate regional groups of commissioners, providers and service users working together, sharing practice and disseminating new policy and guidance;</p><p>- offering bespoke support packages to local authorities where necessary; and</p><p>- promoting the use of naloxone and training people how to use it across the North East.</p><p>Nationally, PHE has issued advice on providing naloxone, published updated clinical guidelines for drug treatment and worked with a network of treatment providers to establish good practice guidance on managing drug-related death risk factors and to improve partnership between treatment providers and other healthcare services.</p><p>PHE has also established a new Public Health Outcomes Framework indicator on drug-related deaths to enable local areas benchmark their performance against others.</p><p> </p><p>Ongoing national work by PHE to help prevent drug-related deaths includes:</p><p> </p><p>- helping local authorities improve their drug-related death review process;</p><p>- helping local authorities increase the number of people with drug problems who are in drug treatment; and</p><p>- improving intelligence on the adverse health effects of drugs.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 7238 7468 question first answered 12/09/2017 16:29:45 answering member 4067 label Biography information for Steve Brine
	tabling member	3973 label Biography information for Grahame Morris

807191

	registered interest
	date	15/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the commercial agreement announced by NHS England on 9 November 2017, what the timetable is for NICE to issue final guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	119837
	answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>The timetable for the National Institute for Health and Care Excellence’s (NICE) guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer is still to be confirmed. Perjeta remains available to new and existing National Health Service patients through the Cancer Drugs Fund pending NICE’s final guidance.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 11:38:14 answering member 4067 label Biography information for Steve Brine
	tabling member	4509 label Biography information for Craig Tracey

748694

	registered interest
	date	05/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mechanical Thrombectomy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the announcement by NHS England of 11 April 2017 on mechanical thrombectomy, when the assessment of the readiness of each of the 24 neuroscience centres to carry out mechanical thrombectomy will be completed; and whether the results of this assessment will be published.
	tabling member constituency	Chesham and Amersham
	tabling member printed	Mrs Cheryl Gillan
	uin	3250
	answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>NHS England agreed to fund thrombectomy for stroke in April 2017.</p><p>Progression to full implementation will need to take place on a phased basis to ensure the service providers can put in place the necessary staffing and working arrangements. In the short term there will be an interim set of arrangements.</p><p>Initially the procedure will be undertaken in neuroscience centres which are currently being assessed to ensure that they meet the standards set out in the service specification that is currently out for public consultation. This information will be used by a national oversight group and regional commissioning teams to assess who is able to provide the service in this interim period and will not be published. Further work with the providers of this service will be completed with regional commissioners and the services directly to establish clear action plans which will lead to full implementation.</p><p>It is anticipated that there will be some 1,000 cases completed by the end of March 2018; and that, by 2023, about 10% of stroke admissions in England (8,000 cases) will be treated with thrombectomy annually. NHS England have not undertaken an independent cost benefit analysis of thrombectomy but there have been research studies published such as Jean Ganesalingam et al – “Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers”, in Acute Ischemic Stroke 2015;46:2591-2598. This showed that it is a highly cost effective treatment, particularly when the longer term health and social care costs are taken into account.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 3249 3251 question first answered 13/07/2017 13:02:42 answering member 4067 label Biography information for Steve Brine
	tabling member	18 label Biography information for Dame Cheryl Gillan

748695

	registered interest
	date	05/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mechanical Thrombectomy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the announcement by NHS England of 11 April 2017 on mechanical thrombectomy, when NHS England will start to commission mechanical thrombectomy; when it is planned that the first 1,000 patients will be refitted from mechanical thrombectomy; and when it is planned that 8,000 patients a year will be benefitting from mechanical thrombectomy.
	tabling member constituency	Chesham and Amersham
	tabling member printed	Mrs Cheryl Gillan
	uin	3251
	answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>NHS England agreed to fund thrombectomy for stroke in April 2017.</p><p>Progression to full implementation will need to take place on a phased basis to ensure the service providers can put in place the necessary staffing and working arrangements. In the short term there will be an interim set of arrangements.</p><p>Initially the procedure will be undertaken in neuroscience centres which are currently being assessed to ensure that they meet the standards set out in the service specification that is currently out for public consultation. This information will be used by a national oversight group and regional commissioning teams to assess who is able to provide the service in this interim period and will not be published. Further work with the providers of this service will be completed with regional commissioners and the services directly to establish clear action plans which will lead to full implementation.</p><p>It is anticipated that there will be some 1,000 cases completed by the end of March 2018; and that, by 2023, about 10% of stroke admissions in England (8,000 cases) will be treated with thrombectomy annually. NHS England have not undertaken an independent cost benefit analysis of thrombectomy but there have been research studies published such as Jean Ganesalingam et al – “Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers”, in Acute Ischemic Stroke 2015;46:2591-2598. This showed that it is a highly cost effective treatment, particularly when the longer term health and social care costs are taken into account.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 3249 3250 question first answered 13/07/2017 13:02:43 answering member 4067 label Biography information for Steve Brine
	tabling member	18 label Biography information for Dame Cheryl Gillan

748693

	registered interest
	date	05/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mechanical Thrombectomy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the announcement by NHS England of 11 April 2017 on mechanical thrombectomy, what estimate he has made of the savings in long-term health and social care costs from those stroke patients who receive a mechanical thrombectomy each year.
	tabling member constituency	Chesham and Amersham
	tabling member printed	Mrs Cheryl Gillan
	uin	3249
	answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>NHS England agreed to fund thrombectomy for stroke in April 2017.</p><p>Progression to full implementation will need to take place on a phased basis to ensure the service providers can put in place the necessary staffing and working arrangements. In the short term there will be an interim set of arrangements.</p><p>Initially the procedure will be undertaken in neuroscience centres which are currently being assessed to ensure that they meet the standards set out in the service specification that is currently out for public consultation. This information will be used by a national oversight group and regional commissioning teams to assess who is able to provide the service in this interim period and will not be published. Further work with the providers of this service will be completed with regional commissioners and the services directly to establish clear action plans which will lead to full implementation.</p><p>It is anticipated that there will be some 1,000 cases completed by the end of March 2018; and that, by 2023, about 10% of stroke admissions in England (8,000 cases) will be treated with thrombectomy annually. NHS England have not undertaken an independent cost benefit analysis of thrombectomy but there have been research studies published such as Jean Ganesalingam et al – “Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers”, in Acute Ischemic Stroke 2015;46:2591-2598. This showed that it is a highly cost effective treatment, particularly when the longer term health and social care costs are taken into account.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 3250 3251 question first answered 13/07/2017 13:02:42 answering member 4067 label Biography information for Steve Brine
	tabling member	18 label Biography information for Dame Cheryl Gillan

748143

	registered interest
	date	04/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Teachers: Training
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Prime Minister's press release of 27 January 2017, PM: mental health training for teachers will make a real difference to children's lives, how much it will cost to train each teacher that undergoes the mental health training programme provided by Mental Health First Aid England.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	2856
	answer	answer is ministerial correction date of answer 10/07/2017 answer text <p>The Government is committed to offering Mental Health First Aid training to a teacher in every secondary school by 2019. The training programme has been developed to be delivered as a one day training session.</p><p>The Department is working closely with Mental Health First Aid England to monitor the implementation of the training. The Department does not hold the rest of the information in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2854 2857 question first answered 10/07/2017 16:41:56 answering member 4067 label Biography information for Steve Brine
	tabling member	4036 label Biography information for Luciana Berger

748144

	registered interest
	date	04/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Teachers: Training
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Prime Minister's press release of 27 January 2017, PM: mental health training for teachers will make a real difference to children's lives, how many days of mental health training will be provided to each teacher.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	2854
	answer	answer is ministerial correction date of answer 10/07/2017 answer text <p>The Government is committed to offering Mental Health First Aid training to a teacher in every secondary school by 2019. The training programme has been developed to be delivered as a one day training session.</p><p>The Department is working closely with Mental Health First Aid England to monitor the implementation of the training. The Department does not hold the rest of the information in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2856 2857 question first answered 10/07/2017 16:41:56 answering member 4067 label Biography information for Steve Brine
	tabling member	4036 label Biography information for Luciana Berger

748145

	registered interest
	date	04/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Teachers: Training
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Prime Minister's press release of 27 January 2017, PM: mental health training for teachers will make a real difference to children's lives, (a) how many teachers have been trained by Mental Health First Aid England and (b) how much of the £200,000 allocated by the Government for that training has been spent.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	2857
	answer	answer is ministerial correction date of answer 10/07/2017 answer text <p>The Government is committed to offering Mental Health First Aid training to a teacher in every secondary school by 2019. The training programme has been developed to be delivered as a one day training session.</p><p>The Department is working closely with Mental Health First Aid England to monitor the implementation of the training. The Department does not hold the rest of the information in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2854 2856 question first answered 10/07/2017 16:41:56 answering member 4067 label Biography information for Steve Brine
	tabling member	4036 label Biography information for Luciana Berger

767576

	registered interest
	date	09/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the NHS and Public Health England HIV PrEP impact trial, what steps his Department is taking to ensure that the revised start date for the trial is not missed.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	106653
	answer	answer is ministerial correction date of answer 17/10/2017 answer text <p>NHS England will enrol 10,000 participants over three years at clinics across the country in the pre-exposure prophylaxis (PrEP) IMPACT trial. The trial will provide data on implementation of PrEP and its impact on HIV transmission among high-risk groups, not those at any risk.</p><p> </p><p>Individuals for enrolment to the trial will be assessed against inclusion and exclusion criteria in order to target those at high risk of getting HIV and therefore most likely to benefit. National Health Service funded access to PrEP drugs is only available through the IMPACT trial.</p><p> </p><p>NHS England and Public Health England have been actively supporting the PrEP IMPACT trial sponsor in accelerating ethical approval and trial site recruitment. It was not possible to complete all the necessary steps to achieve a September 2017 start because of the large number of trial sites. Trial sites have to assure the trial co-ordination centre has ethical approval, drug procurement, trial site feasibility assessments, trial site training, local commissioner approval and local research governance approval in place before permission to recruit is given. This is dependent on local processes and is variable. Trial opening dates will be staggered to reflect this.</p><p> </p><p>The first clinics began be enrolling patients in October and a number of clinics will be opening within weeks of each other, both in and outside London. The trial sponsor anticipates that up to 70 sites will be enrolling patients by the end of November. All clinics should be enrolling patients by April 2018.</p><p> </p><p>As the largest single study of its type in the world, the PrEP trial is complex, involving well in excess of 100 organisations ranging from sexual health clinics, local authority commissioners, research bodies, and a drug manufacturer. The aim is to ensure multiple clinics across the country can provide geographical access and avoid surges to individual clinics. As trial sites open, information will be uploaded to the trial website enabling individuals who wish to participate in the trial to identify their nearest local clinic.</p><p> </p><p>Of the 10,000 trial places, an initial 2,000 places are being reserved for groups at high HIV risk other than gay men. The trial co-ordinating team will monitor PrEP uptake and keep this initial ring-fence under review.</p><p> </p><p>Further information on the trial can be found at the following link:</p><p> </p><p>https://www.prepimpacttrial.org.uk/</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106543 106651 106652 106654 106655 question first answered 17/10/2017 16:48:49 answering member 4067 label Biography information for Steve Brine
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

767579

	registered interest
	date	09/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the NHS and Public Health England HIV PrEP impact trial, what steps his Department has taken to ensure that some trial places are reserved for under-represented groups.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	106652
	answer	answer is ministerial correction date of answer 17/10/2017 answer text <p>NHS England will enrol 10,000 participants over three years at clinics across the country in the pre-exposure prophylaxis (PrEP) IMPACT trial. The trial will provide data on implementation of PrEP and its impact on HIV transmission among high-risk groups, not those at any risk.</p><p> </p><p>Individuals for enrolment to the trial will be assessed against inclusion and exclusion criteria in order to target those at high risk of getting HIV and therefore most likely to benefit. National Health Service funded access to PrEP drugs is only available through the IMPACT trial.</p><p> </p><p>NHS England and Public Health England have been actively supporting the PrEP IMPACT trial sponsor in accelerating ethical approval and trial site recruitment. It was not possible to complete all the necessary steps to achieve a September 2017 start because of the large number of trial sites. Trial sites have to assure the trial co-ordination centre has ethical approval, drug procurement, trial site feasibility assessments, trial site training, local commissioner approval and local research governance approval in place before permission to recruit is given. This is dependent on local processes and is variable. Trial opening dates will be staggered to reflect this.</p><p> </p><p>The first clinics began be enrolling patients in October and a number of clinics will be opening within weeks of each other, both in and outside London. The trial sponsor anticipates that up to 70 sites will be enrolling patients by the end of November. All clinics should be enrolling patients by April 2018.</p><p> </p><p>As the largest single study of its type in the world, the PrEP trial is complex, involving well in excess of 100 organisations ranging from sexual health clinics, local authority commissioners, research bodies, and a drug manufacturer. The aim is to ensure multiple clinics across the country can provide geographical access and avoid surges to individual clinics. As trial sites open, information will be uploaded to the trial website enabling individuals who wish to participate in the trial to identify their nearest local clinic.</p><p> </p><p>Of the 10,000 trial places, an initial 2,000 places are being reserved for groups at high HIV risk other than gay men. The trial co-ordinating team will monitor PrEP uptake and keep this initial ring-fence under review.</p><p> </p><p>Further information on the trial can be found at the following link:</p><p> </p><p>https://www.prepimpacttrial.org.uk/</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106543 106651 106653 106654 106655 question first answered 17/10/2017 16:48:48 answering member 4067 label Biography information for Steve Brine
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

767578

	registered interest
	date	09/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the NHS and Public Health England HIV PrEP impact trial, what steps he is taking to ensure that people in areas that are not included in that trial can access this treatment.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	106651
	answer	answer is ministerial correction date of answer 17/10/2017 answer text <p>NHS England will enrol 10,000 participants over three years at clinics across the country in the pre-exposure prophylaxis (PrEP) IMPACT trial. The trial will provide data on implementation of PrEP and its impact on HIV transmission among high-risk groups, not those at any risk.</p><p> </p><p>Individuals for enrolment to the trial will be assessed against inclusion and exclusion criteria in order to target those at high risk of getting HIV and therefore most likely to benefit. National Health Service funded access to PrEP drugs is only available through the IMPACT trial.</p><p> </p><p>NHS England and Public Health England have been actively supporting the PrEP IMPACT trial sponsor in accelerating ethical approval and trial site recruitment. It was not possible to complete all the necessary steps to achieve a September 2017 start because of the large number of trial sites. Trial sites have to assure the trial co-ordination centre has ethical approval, drug procurement, trial site feasibility assessments, trial site training, local commissioner approval and local research governance approval in place before permission to recruit is given. This is dependent on local processes and is variable. Trial opening dates will be staggered to reflect this.</p><p> </p><p>The first clinics began be enrolling patients in October and a number of clinics will be opening within weeks of each other, both in and outside London. The trial sponsor anticipates that up to 70 sites will be enrolling patients by the end of November. All clinics should be enrolling patients by April 2018.</p><p> </p><p>As the largest single study of its type in the world, the PrEP trial is complex, involving well in excess of 100 organisations ranging from sexual health clinics, local authority commissioners, research bodies, and a drug manufacturer. The aim is to ensure multiple clinics across the country can provide geographical access and avoid surges to individual clinics. As trial sites open, information will be uploaded to the trial website enabling individuals who wish to participate in the trial to identify their nearest local clinic.</p><p> </p><p>Of the 10,000 trial places, an initial 2,000 places are being reserved for groups at high HIV risk other than gay men. The trial co-ordinating team will monitor PrEP uptake and keep this initial ring-fence under review.</p><p> </p><p>Further information on the trial can be found at the following link:</p><p> </p><p>https://www.prepimpacttrial.org.uk/</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106543 106652 106653 106654 106655 question first answered 17/10/2017 16:48:48 answering member 4067 label Biography information for Steve Brine
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

767577

	registered interest
	date	09/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the NHS and Public Health England HIV PrEP impact trial, what assessment he has made of the reasons why the target trial start date of September 2017 was not met.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	106654
	answer	answer is ministerial correction date of answer 17/10/2017 answer text <p>NHS England will enrol 10,000 participants over three years at clinics across the country in the pre-exposure prophylaxis (PrEP) IMPACT trial. The trial will provide data on implementation of PrEP and its impact on HIV transmission among high-risk groups, not those at any risk.</p><p> </p><p>Individuals for enrolment to the trial will be assessed against inclusion and exclusion criteria in order to target those at high risk of getting HIV and therefore most likely to benefit. National Health Service funded access to PrEP drugs is only available through the IMPACT trial.</p><p> </p><p>NHS England and Public Health England have been actively supporting the PrEP IMPACT trial sponsor in accelerating ethical approval and trial site recruitment. It was not possible to complete all the necessary steps to achieve a September 2017 start because of the large number of trial sites. Trial sites have to assure the trial co-ordination centre has ethical approval, drug procurement, trial site feasibility assessments, trial site training, local commissioner approval and local research governance approval in place before permission to recruit is given. This is dependent on local processes and is variable. Trial opening dates will be staggered to reflect this.</p><p> </p><p>The first clinics began be enrolling patients in October and a number of clinics will be opening within weeks of each other, both in and outside London. The trial sponsor anticipates that up to 70 sites will be enrolling patients by the end of November. All clinics should be enrolling patients by April 2018.</p><p> </p><p>As the largest single study of its type in the world, the PrEP trial is complex, involving well in excess of 100 organisations ranging from sexual health clinics, local authority commissioners, research bodies, and a drug manufacturer. The aim is to ensure multiple clinics across the country can provide geographical access and avoid surges to individual clinics. As trial sites open, information will be uploaded to the trial website enabling individuals who wish to participate in the trial to identify their nearest local clinic.</p><p> </p><p>Of the 10,000 trial places, an initial 2,000 places are being reserved for groups at high HIV risk other than gay men. The trial co-ordinating team will monitor PrEP uptake and keep this initial ring-fence under review.</p><p> </p><p>Further information on the trial can be found at the following link:</p><p> </p><p>https://www.prepimpacttrial.org.uk/</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106543 106651 106652 106653 106655 question first answered 17/10/2017 16:48:49 answering member 4067 label Biography information for Steve Brine
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

748702

	registered interest
	date	05/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the NHS England review on ending prescriptions for certain items that can be purchased over the counter, (a) which items are being reviewed and (b) how many and which items are projected to be reviewed during the current Parliament.
	tabling member constituency	Stretford and Urmston
	tabling member printed	Kate Green
	uin	3003
	answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>NHS England is leading a review of medicines which may be considered as being of low clinical value and is working with NHS Clinical Commissioners to develop new guidance for clinical commissioning groups. NHS England expects to publish a consultation on the draft guidance shortly. The Department has not made an impact assessment on this work.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 3004 3005 3008 question first answered 13/07/2017 12:59:07 answering member 4067 label Biography information for Steve Brine
	tabling member	4120 label Biography information for Kate Green

780531

	registered interest
	date	30/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the NHS England publication, GE3 Hospital Medicines Optimisation and the Biological Medicines Commissioning Framework on 12 September 2017, what criteria his Department has set to determine the best value biologic.
	tabling member constituency	West Ham
	tabling member printed	Lyn Brown
	uin	110253
	answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>It is important that patients and clinicians together determine which is the best value biologic appropriate to an individual’s clinical needs. We consider that both cost to the National Health Service and clinical appropriateness for a patient should be used by patients and clinicians to determine best value.</p><p> </p><p>NHS England will be working with pharmacy procurement specialists, with input from clinicians and patients, to determine the best approach. The aim will be to strike the right balance between individual patient need and good value for the NHS.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/11/2017 17:21:06 answering member 4067 label Biography information for Steve Brine
	tabling member	1583 label Biography information for Ms Lyn Brown

804559

	registered interest
	date	11/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the NHS England document, Next Steps on the Five Year Forward View published in March 2017, what recent progress the NHS has made on meeting the objective for an extra 5,000 people to survive cancer over the next two years.
	tabling member constituency	Leicester South
	tabling member printed	Jonathan Ashworth
	uin	118761
	answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>Earlier and faster diagnosis is key to improving survival rates and NHS England is investing over £200 million over the next two years in cancer services to encourage local areas to find new and innovative ways to diagnose cancer earlier, improve the care for those living with cancer and ensure each cancer patient gets the right care for them. The Government has also committed £130 million for new technology and equipment to ensure patients have access to the best and latest radiotherapy treatment.</p><p> </p><p>Survival rates from cancer in England are at a record high, and since 2010 rates of survival from cancer have increased year-on-year. The decrease in cancer deaths means that around 7,000 people are alive today who would not have been had things stayed the same. One year survival rates for the period 2017-19 will be available in 2021.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/12/2017 17:30:05 answering member 4067 label Biography information for Steve Brine
	tabling member	4244 label Biography information for Jonathan Ashworth

818651

	registered interest
	date	08/01/2018
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Innovative Medicines and Medical Technology Review
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Government response to the Accelerated Access Review published in November 2017, what plans his Department has to streamline existing routes to market for medical technologies, devices and diagnostics.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	121415
	answer	answer is ministerial correction date of answer 16/01/2018 answer text <p>We are introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions, getting breakthrough products that we believe will be truly transformative to patients more quickly. A new Accelerated Access Collaborative (AAC) chaired by Sir Andrew Witty, will develop and own the Accelerated Access Pathway which will be operational from April 2018. All products including medical technologies, devices and diagnostics will be eligible for selection. In addition to the new Pathway, the AAC will also make recommendations to the Government and its partners about opportunities to further streamline existing routes to market.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2018 12:04:46 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

748180

	registered interest
	date	04/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mental Health Services: Recruitment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the GP Forward Review published in April 2016, how many of the 3,000 new mental health therapists referenced in that review have been appointed.
	tabling member constituency	Sefton Central
	tabling member printed	Bill Esterson
	uin	2846
	answer	answer is ministerial correction date of answer 10/07/2017 answer text <p>This information is not available in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/07/2017 16:31:24 answering member 4067 label Biography information for Steve Brine
	tabling member	4061 label Biography information for Bill Esterson

818756

	registered interest
	date	08/01/2018
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	High Weald Lewes Havens Clinical Commissioning Group
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 8 November 2016 to Question 51429, if he will publish a copy of the validated analysis of costs provided by Coperforma Ltd to the High Weald Havens Clinical Commissioning Group referred to in that Answer; what the value is of invoices the High Weald Havens Clinical Commissioning Group received directly from each trust which incurred private ambulance costs arising from performance problems with Patient Transport Services provided by Coperforma and arms length driver operatives; and if he will make a statement.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	121520
	answer	answer is ministerial correction date of answer 16/01/2018 answer text <p>The information requested is not collected centrally.</p><p>The provision of patient transport services is a matter for local National Health Service commissioners. NHS England has advised that High Weald Havens Clinical Commissioning Group commissioned an independent investigation into these events, which reported in March 2017. Accordingly, there are no plans to undertake a further independent investigation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 121516 121517 question first answered 16/01/2018 16:19:44 answering member 4067 label Biography information for Steve Brine
	tabling member	3930 label Biography information for Caroline Lucas

748214

	registered interest
	date	04/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Carers
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 7 March 2017 to Question 66131, on carers, what plans he has to publish the national carers strategy.
	tabling member constituency	Worsley and Eccles South
	tabling member printed	Barbara Keeley
	uin	2923
	answer	answer is ministerial correction date of answer 10/07/2017 answer text <p><strong></strong>The Government remains committed to supporting carers to provide care as they would wish, and to do so in a way that supports their own health and wellbeing, employment and wider life chances.</p><p>We have said that more widely we will consult on proposals to improve social care. Next steps will be set out in due course.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/07/2017 16:31:40 answering member 4067 label Biography information for Steve Brine
	tabling member	1588 label Biography information for Barbara Keeley

751371

	registered interest
	date	12/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Commissioning Support Units
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 7 March 2017 to Question 65785, on commissioning support units, if he will set out the timetable for a formal decision on the autonomy of such units.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	4638
	answer	answer is ministerial correction date of answer 20/07/2017 answer text <p>The decision on whether to make Commissioning Support Units autonomous has been deferred until NHS England has decided how these units can be best positioned to support Sustainability and Transformation Partnerships and the move to develop Accountable Care Systems. They expect to be in a position to consider this later this year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2017 15:11:17 answering member 4067 label Biography information for Steve Brine
	tabling member	4444 label Biography information for Karin Smyth

788557

	registered interest
	date	13/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Gluten-free Foods: Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 27 April 2017 to Question 71681, on Coeliac disease: prescriptions, what plans he has to protect those who manufacture gluten-free products from the effect of the proposed removal of gluten-free products from prescriptions.
	tabling member constituency	Barnsley Central
	tabling member printed	Dan Jarvis
	uin	112718
	answer	answer is ministerial correction date of answer 16/11/2017 answer text <p>In March this year, the Department ran a 12 week public consultation on the availability of gluten free foods on prescription. Nearly 8,000 responses were received and these are currently being analysed. The Government is committed to ensuring maximum value for patients and service users from every pound spent in the National Health Service. While we would not want to see manufacturers disadvantaged as a result of any decision we may take, no decision has yet been made on the removal of gluten-free products from prescriptions and we cannot pre-empt the outcome of the consultation.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/11/2017 12:26:37 answering member 4067 label Biography information for Steve Brine
	tabling member	4243 label Biography information for Dan Jarvis

748571

	registered interest
	date	05/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sustainability and Transformation Partnerships: Consultants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 26 April 2017 to Question 71179, if he will require all sustainability and transformation partnerships to publish the total amount paid to private consultants for providing advice.
	tabling member constituency	Ellesmere Port and Neston
	tabling member printed	Justin Madders
	uin	3067
	answer	answer is ministerial correction date of answer 12/07/2017 answer text <p>NHS England do not plan to require Sustainability and Transformation Partnership (STP) areas to publish the total amount paid to companies who advise and/or support the delivery of improved health and social care.</p><p> </p><p>It is for each STP area to decide where they may need support or advice from external organisations and normal value for money rules apply. However, all partners within each STP area need to be disciplined about keeping costs as low as possible as they work to alleviate pressures on the National Health Service, and improve patient care.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/07/2017 09:14:00 answering member 4067 label Biography information for Steve Brine
	tabling member	4418 label Biography information for Justin Madders

754113

	registered interest
	date	19/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dental Health: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 24 April 2017 to Question 70854, if he will make an assessment of the merits of re-investing money from unused units of dental activity into a national early intervention programme for tackling child tooth decay.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	6315
	answer	answer is ministerial correction date of answer 05/09/2017 answer text <p>At the request of Ministers, NHS England is setting up a scheme in 13 high needs areas to improve the oral health of young children. The scheme will be based in dental practices and will have a particular focus on those children who do not currently visit the dentist. The scheme is expected to be launched in the next few months and will be funded from existing dental resources, including unused units of dental activity. Evaluation has been designed in from the start and the learning, once available, will inform the approach going forward.</p><p> </p><p>NHS England advises that the West Midlands scheme is still under consideration following local discussions this month. The scheme would incentivise dentists to see more children under the age of two. Decisions on the future of the scheme are expected to be taken next month.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 6314 question first answered 05/09/2017 14:26:32 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

754112

	registered interest
	date	19/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dental Health: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 24 April 2017 to Question 70314, what progress his Department has made on determining the scope of and implementing the early intervention scheme for oral health.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	6314
	answer	answer is ministerial correction date of answer 05/09/2017 answer text <p>At the request of Ministers, NHS England is setting up a scheme in 13 high needs areas to improve the oral health of young children. The scheme will be based in dental practices and will have a particular focus on those children who do not currently visit the dentist. The scheme is expected to be launched in the next few months and will be funded from existing dental resources, including unused units of dental activity. Evaluation has been designed in from the start and the learning, once available, will inform the approach going forward.</p><p> </p><p>NHS England advises that the West Midlands scheme is still under consideration following local discussions this month. The scheme would incentivise dentists to see more children under the age of two. Decisions on the future of the scheme are expected to be taken next month.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 6315 question first answered 05/09/2017 14:26:32 answering member 4067 label Biography information for Steve Brine
	tabling member	298 label Biography information for Steve McCabe

772212

	registered interest
	date	17/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 21 November 2016 to Question 52567, on prescription drugs, what further steps have been taken to reduce the amount of unused prescription medication; and what the cost to the public purse was of those steps.
	tabling member constituency	Southampton, Itchen
	tabling member printed	Royston Smith
	uin	108352
	answer	answer is ministerial correction date of answer 25/10/2017 answer text <p>The approach NHS England is taking in respect of medicines optimisation is outlined in the document Next Steps on the Five Year Forward View, published in March this year. This sets out that four Regional Medicines Optimisation Committees (RMOCs) will coordinate the pursuit of medicines optimisation opportunities, including in care homes, multiple prescribing, use of generics and biosimilars, and reducing medicines wastage.</p><p> </p><p>The RMOCs became operational in April and activity for each RMOC currently focuses on priorities identified for delivery through the Medicines Optimisation workstream of NHS England's Medicines Value Programme.</p><p> </p><p>The Department does not collect information on the costs of the steps being taken. This is part of NHS England’s overall budget for the National Health Service. However, we understand the cost to the public purse of establishing the RMOCs has been minimal and has, to date, been primarily associated with their set up. It is vital that patients get the best outcomes from their medicines, waste is reduced and taxpayers get the best value from the use of medicines in the NHS.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 25/10/2017 16:04:43 answering member 4067 label Biography information for Steve Brine
	tabling member	4478 label Biography information for Royston Smith

732509

	registered interest
	date	26/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Microplastics: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 18 April 2017 to Question 70013, for what reasons that Answer does not refer to the reasons why his Department is not planning to conduct an assessment of the implications of microplastics entering the marine environment on human health.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	1230
	answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The United Kingdom Government, from an environmental perspective, is conducting research on the capacity for microplastics to cause harm in the marine environment and implications for the food chain. The most likely human exposure to microplastics from the marine environment is via the ingestion of seafood.</p><p> </p><p>The Food Standards Agency (FSA) has been monitoring the scientific evidence concerning the occurrence and effects of microplastics in seafood. On the basis of current information, the FSA considers it is unlikely that the presence of the low levels of microplastic particles that have been reported to occur in certain types of seafood would cause harm to consumers. The FSA will continue to monitor and assess emerging information concerning microplastics in food.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2017 11:18:49 answering member 4067 label Biography information for Steve Brine
	tabling member	1447 label Biography information for Andrew Rosindell

785140

	registered interest
	date	06/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dietary Supplements
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 13 April 2016 to Question 32737, on malnutrition, whether he plans to revise national guidance on food supplements.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	111712
	answer	answer is ministerial correction date of answer 14/11/2017 answer text <p>There are currently no plans to review national guidance on food supplements.</p><p> </p><p>Most people should be able to get all the nutrients they need from eating a diet consistent with the Eatwell Guide, provided by Public Health England. Supplements, therefore, are only recommended for a small number of population groups and advice is available on the NHS Choices website:</p><p><a href="https://www.nhs.uk/chq/pages/1122.aspx?categoryid=51" target="_blank">https://www.nhs.uk/chq/pages/1122.aspx?categoryid=51</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/11/2017 12:05:01 answering member 4067 label Biography information for Steve Brine
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

800927

	registered interest
	date	05/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drug: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Advisory Council on the Misuse of Drugs report Commissioning impact on drug treatment which published in September 2017, what assessment he has made of the effect of reductions in funding for local authorities on the availability of drug misuse treatment in England.
	tabling member constituency	Manchester, Withington
	tabling member printed	Jeff Smith
	uin	117486
	answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>Officials are currently reviewing the report by the Advisory Council on the Misuse of Drugs entitled Commissioning impact of on drug treatment published on 6 September. The Government will respond shortly.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:39:29 answering member 4067 label Biography information for Steve Brine
	tabling member	4456 label Biography information for Jeff Smith

802709

	registered interest
	date	07/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Life Sciences
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to page 13 of the life sciences sector deal published on 6 December 2017, what steps the Government plans to take to improve NHS England’s commercial capacity and capability.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	118258
	answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>The Government and its partner bodies, including NHS England, recently published the response to the Accelerated Access Review setting out plans to improve NHS England’s commercial capacity and capability in relation to medicines procurement as well as the negotiation of bespoke commercial access arrangements for high cost drugs.</p><p> </p><p>While establishing this commercial function is an operational matter for NHS England, the Government has already taken steps to support this process by transferring the Commercial Medicines Unit from the Department to NHS England on 1 April 2017. In addition, transferring the role of agreeing future Patient Access Schemes (PAS) from the Department to NHS England means that companies need to begin only one dialogue for each medicine.</p><p> </p><p>NHS England is currently in the process of recruiting a number of other key posts to support this commercial function more broadly.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/12/2017 17:15:26 answering member 4067 label Biography information for Steve Brine
	tabling member	4124 label Biography information for Chi Onwurah

746917

	registered interest
	date	29/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the timeline for the next steps of the trial referred to in the announcement will be published.
	tabling member constituency	Hazel Grove
	tabling member printed	Mr William Wragg
	uin	2010
	answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.</p><p> </p><p>NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:</p><p><a href="https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england" target="_blank">https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england</a></p><p> </p><p>The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.</p><p> </p><p>The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.</p><p> </p><p>The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.</p><p> </p><p>Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2009 2011 2012 2013 question first answered 04/07/2017 11:10:26 answering member 4067 label Biography information for Steve Brine
	tabling member	4429 label Biography information for Mr William Wragg

746918

	registered interest
	date	29/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the frequently asked questions document referred to in the announcement will be published.
	tabling member constituency	Hazel Grove
	tabling member printed	Mr William Wragg
	uin	2011
	answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.</p><p> </p><p>NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:</p><p><a href="https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england" target="_blank">https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england</a></p><p> </p><p>The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.</p><p> </p><p>The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.</p><p> </p><p>The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.</p><p> </p><p>Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2009 2010 2012 2013 question first answered 04/07/2017 11:10:26 answering member 4067 label Biography information for Steve Brine
	tabling member	4429 label Biography information for Mr William Wragg